Quantcast
Last updated on April 21, 2014 at 7:52 EDT

Latest BioSpecifics Technologies Corp. Stories

2011-08-31 18:02:00

MALVERN, Pa. and LYNBROOK, N.Y., Aug. 31, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, and BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company, today announced that they have dismissed all pending litigation between the Companies and announced plans to move XIAFLEX forward in the clinic for cellulite and human and canine lipoma as well as to collaborate on the initiation of further studies for XIAFLEX...

2011-08-09 06:00:00

LYNBROOK, N.Y., Aug. 9, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Eurasia, today announced its financial results for the second quarter ended June 30, 2011 and provided a corporate update. For the quarter, the Company reported net income of $2.6 million or $0.40 per share on a basic basis and $0.36...

2011-08-02 07:00:00

LYNBROOK, N.Y., Aug. 2, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced today that it will host a conference call and live audio webcast at 8:30am EDT on Tuesday, August 9, 2011 to report its second quarter 2011 financial results and corporate highlights. The Company will be hosting a conference call to discuss these financial results and provide a corporate update. In order to...

2011-06-20 06:00:00

LYNBROOK, N.Y., June 20, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC; the "Company"), a biopharmaceutical company developing first in class collagenase-based products, today announced that its Board of Directors has reauthorized the stock repurchase program under which the Company is authorized to repurchase up to $2 million of its outstanding common stock. This decision reflects the Company's continued commitment to increasing value for its stockholders and its...

2011-06-02 15:15:00

LYNBROOK, N.Y., June 2, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Jefferies 2011 Global Healthcare Conference in New York on Thursday, June 9, 2011 at 3:30pm EDT. A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's...

2011-06-01 06:00:00

LYNBROOK, N.Y., June 1, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that positive data for XIAPEX® (clostridial collagenase histolyticum for injection) were presented at the XVIth Annual Federation of European Societies for Surgery of the Hand (FESSH) Congress which took place in Oslo, Norway at the Oslo Congress Centre on May 26-28, 2011. Pfizer...

2011-05-20 15:00:00

LYNBROOK, N.Y., May 20, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today provided an update on the launch progress of XIAPEX® (collagenase clostridium histolyticum) in Europe. As reported by BioSpecifics' strategic partner, Auxilium Pharmaceuticals, Inc. (Auxilium), XIAPEX is now available for sale by Pfizer, Inc. (Pfizer) in 7 European countries: the United Kingdom,...

2011-05-18 15:15:00

LYNBROOK, N.Y., May 18, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that there will be three separate presentations on collagenase clostridium histolyticum (trademarked XIAPEX® in Europe) for the treatment of patients suffering from Dupuytren's contracture at the upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting...

2011-05-11 15:34:00

LYNBROOK, N.Y., May 11, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at SEVEN, Noble Financial Capital Markets' Seventh Annual Equity Conference on Tuesday, May 17th at 9:30am EDT at the Hard Rock Hotel in Hollywood, Florida. A live webcast of the presentation can be accessed under "Calendar of Events" in the...

2011-05-10 15:01:00

LYNBROOK, N.Y., May 10, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the first quarter ended March 31, 2011 and provided a corporate update. For the quarter, the Company reported a net income of $3.7 million or $0.59 per share on a basic basis and $0.51 on a fully diluted basis. The Company anticipates that it will be profitable on an ongoing...